NCT06559033 Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS
| NCT ID | NCT06559033 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Rouen |
| Condition | Monoclonal Gammopathy of Undetermined Significance |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-10-07 |
| Primary Completion | 2026-10-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2025-10-07 with a primary completion date of 2026-10-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophysiological mechanisms would make it possible to propose treatments specifically targeting the deregulated pathways.
Eligibility Criteria
Inclusion Criteria: * Major patients with multiple myeloma (MM) (defined by clonal proliferation of tumour plasma cells (\>10%), presence of a monoclonal peak in serum or urine (excluding non-secretory myeloma) and organ involvement secondary to bone marrow invasion) or with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g/L and no clinical involvement). * Membership of a social security scheme * Adult having read and understood the information letter and signed the consent form Exclusion Criteria: * Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub-guardianship or guardianship
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06559033 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Monoclonal Gammopathy of Undetermined Significance. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06559033 currently recruiting?
Yes, NCT06559033 is actively recruiting participants. Contact the research team at Abdellah.Tebani@chu-rouen.fr for enrollment information.
Where is the NCT06559033 trial being conducted?
This trial is being conducted at Rouen, France, Rouen, France.
Who is sponsoring the NCT06559033 clinical trial?
NCT06559033 is sponsored by University Hospital, Rouen. The trial plans to enroll 300 participants.